Search research articles
Contact Us
Filters
Showing results (11-20 of 49) with videos related to
Page
of 5
Sort By:
The Journal of Antimicrobial Chemotherapy
|
June 3, 2025
Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women
Sharana Mahomed, Martin Beliveau, Roberto Heredia-Ortiz, et al.
Cell
|
August 18, 2015
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
Masaru Kanekiyo, Wei Bu, M Gordon Joyce, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 14, 2020
Antibody reactivity to SARS-CoV-2 is common in unexposed adults and infants under 6 months
Abdelilah Majdoubi, Christina Michalski, Sarah E O'Connell, et al.
Nature Chemical Biology
|
August 22, 2017
Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529
Marie Pancera, Yen-Ting Lai, Tatsiana Bylund, et al.
Nature Communications
|
November 28, 2024
Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa
Maria P Lemos, Rena D Astronomo, Yunda Huang, et al.
Journal of Clinical Pharmacology
|
June 9, 2025
Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of a Pair of Anti-HIV Monoclonal Antibodies, VRC01 and VRC01LS, in Adults without HIV
Yunda Huang, Lily Zhang, Maria P Lemos, et al.
JCI Insight
|
March 15, 2021
A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2
Abdelilah Majdoubi, Christina Michalski, Sarah E O'Connell, et al.
The Lancet. HIV
|
March 31, 2023
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial
Sharana Mahomed, Nigel Garrett, Edmund V Capparelli, et al.
NPJ Vaccines
|
January 26, 2021
Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center
Leila Eslamizar, Constantinos Petrovas, David J Leggat, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
September 12, 2022
Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children
Edmund V Capparelli, Gbolahan Ajibola, Kenneth Maswabi, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 49) with videos related to
Sort By:
Page
of 5
The Journal of Antimicrobial Chemotherapy
|
June 3, 2025
Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women
Sharana Mahomed, Martin Beliveau, Roberto Heredia-Ortiz, et al.
Cell
|
August 18, 2015
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
Masaru Kanekiyo, Wei Bu, M Gordon Joyce, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 14, 2020
Antibody reactivity to SARS-CoV-2 is common in unexposed adults and infants under 6 months
Abdelilah Majdoubi, Christina Michalski, Sarah E O'Connell, et al.
Nature Chemical Biology
|
August 22, 2017
Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529
Marie Pancera, Yen-Ting Lai, Tatsiana Bylund, et al.
Nature Communications
|
November 28, 2024
Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa
Maria P Lemos, Rena D Astronomo, Yunda Huang, et al.
Journal of Clinical Pharmacology
|
June 9, 2025
Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of a Pair of Anti-HIV Monoclonal Antibodies, VRC01 and VRC01LS, in Adults without HIV
Yunda Huang, Lily Zhang, Maria P Lemos, et al.
JCI Insight
|
March 15, 2021
A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2
Abdelilah Majdoubi, Christina Michalski, Sarah E O'Connell, et al.
The Lancet. HIV
|
March 31, 2023
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial
Sharana Mahomed, Nigel Garrett, Edmund V Capparelli, et al.
NPJ Vaccines
|
January 26, 2021
Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center
Leila Eslamizar, Constantinos Petrovas, David J Leggat, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
September 12, 2022
Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children
Edmund V Capparelli, Gbolahan Ajibola, Kenneth Maswabi, et al.
Page
of 5